Multi-Metric Subgroup Analysis for Glucose Forecasting in Type 1 Diabetes
Summary
Population-based models improve short-term glucose prediction in Type 1 Diabetes (T1D). These models offer better accuracy than personalized ones, aiding clinicians in optimizing insulin therapy and enhancing glycemic control for T1D patients.
Area of Science:
- Biomedical Engineering
- Artificial Intelligence in Medicine
- Endocrinology
Background:
- Type 1 Diabetes (T1D) management is complex due to intricate glucose regulation.
- Accurate short-term glucose prediction is essential for effective T1D management and reducing complications.
- Existing predictive models often struggle with individual patient variability.
Purpose of the Study:
- To develop and evaluate XGBoost-based predictive models for short-term glucose concentration in T1D patients.
- To compare the performance of population-based versus personalized glucose prediction models.
- To investigate the impact of patient subgroups, including glucose variability, on prediction accuracy.
Main Methods:
- An XGBoost model was developed for glucose prediction at 15, 30, and 60-minute horizons.
- Bayesian optimization was employed to fine-tune the XGBoost model parameters.
- Model performance was assessed across diverse patient subgroups based on glucose patterns and variability.
Main Results:
- The population-based model demonstrated superior performance over personalized models across all prediction horizons.
- Achieved Root Mean Square Error (RMSE) values were 17.39 mg/dL (15 min), 27.28 mg/dL (30 min), and 40.69 mg/dL (60 min).
- Patients with higher glucose variability exhibited reduced prediction accuracy, indicating a challenge for current models.
Conclusions:
- Population-based models show significant potential for enhancing glucose prediction accuracy in T1D.
- Combining population-based approaches with subgroup-specific adjustments can further improve glycemic control.
- Accurate glucose prediction is vital for optimizing insulin therapy and improving patient outcomes in T1D management.
More Related Videos
Related Concept Videos
Diabetes Mellitus: Overview and Type I Subtype
4.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Glucose Homeostasis: Regulation of Blood Glucose
3.7K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
3.7K
Diabetes: Management and Pharmacotherapy
848
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
848
Hormones Regulating Blood Glucose
6.3K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.3K
Diabetes: Symptoms, Diagnosis, and Complications
2.0K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.0K


